XNAS · Biotechnology
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$151.64-3.17%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
50/100
Moderate
Score components
TickerWhale View
Alnylam Pharmaceuticals scores 50 out of 100 overall, which we rate moderate. Quality & growth is its strongest area and Technical its weakest.
What helps
- Quality & growth
- Valuation
What to watch
- Technical
- Risk
- Sentiment Signal
Quality & growth
30%85Strong
- Revenue growth 95.1%
- EPS growth n/a
Valuation
25%70Positive
- P/E 26.0
- EV/Sales 4.2
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
#452 by market cap in our coverage · ~2,500 employees · Listed 2004-05-28 · www.alnylam.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#98 / 139sector rank by TickerWhale Score
TickerWhale Score 50 vs sector average 54.6 (-4.6)
Revenue growth (industry)Top 22%
Gross margin (industry)Top 77%
Return on equity (industry)Top 5%
P/E (industry)Cheaper than 63%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
0/100Weak vs universe
Ranks 0th of 100 covered names on our technical composite — the composite itself scores 6/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
3 buy · 4 sell · 1 neutral of 8 votes
TickerWhale rates ALNY's technical setup weak — 0th percentile of the covered universe. Classic chart indicators lean sell, pointing the same way.
Moving averages
0 / 9constructive
- vs 200-day-45.5%
- vs 50-day-32.7%
Momentum
Constructive
- RSI (14)21 · buy
- Stochasticbuy
- CCIneutral
- Williams %Rbuy
Trend
Weak
- ADX (14) trend strength35· trending
- MACD (12,26,9)sell(histogram -4.681)
How the classic verdict is reached
Moving averages (9) agree on sell — 0 buy vs 9 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 3 sell · 1 neutral.
Result — 3 buy vs 4 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)26.0
- P/S (TTM)4.4
- P/B15.5
- EV/EBITDA—
- EV/Sales4.2
- PEG—
Profitability & returns
- Gross margin79.8%
- Net margin16.8%
- ROE66.5%
- Debt/Equity0.75
Growth
- Revenue growth (YoY)95.1%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $21.0B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $3.7B | $2.2B | $1.8B |
| Gross profit | $3.0B | $1.9B | $1.5B |
| Operating income | $502M | -$177M | -$282M |
| Net income | $314M | -$278M | -$440M |
| EPS (diluted) | $2.33 | $-2.18 | $-3.52 |
| Free cash flow | $465M | -$43M | $42M |
| Cash | $1.7B | $966M | $813M |
| Total debt | $3.0B | $3.1B | $2.7B |
| Equity | $789M | $67M | -$221M |
| Net debt | $1.3B | $2.2B | $1.9B |
| Debt / equity | 3.76 | 46.75 | -12.16 |
| Liabilities / assets | 0.84 | 0.98 | 1.06 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALNYCurrentAlnylam Pharmaceuticals | 50 | 6 | 26.0 | — | 15.5 | 4.2 | $151.64 | -3.17% | +95.1% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.